Barclays Lowers 10x Genomics (NASDAQ:TXG) Price Target to $18.00

10x Genomics (NASDAQ:TXG) had its price objective cut by Barclays from $19.00 to $18.00 in a report released on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms have also recently issued reports on TXG. JPMorgan Chase & Co. reduced their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. UBS Group reduced their price target on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. Citigroup reduced their target price on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Finally, Morgan Stanley dropped their price target on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.79.

10x Genomics Trading Down 15.4 %

Shares of TXG opened at $12.06 on Monday. The business’s 50 day moving average is $14.98 and its 200 day moving average is $17.56. 10x Genomics has a 12-month low of $11.90 and a 12-month high of $51.22. The company has a market capitalization of $1.46 billion, a PE ratio of -7.88 and a beta of 1.85.

Institutional Investors Weigh In On 10x Genomics

Several institutional investors have recently made changes to their positions in TXG. Signaturefd LLC grew its position in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after acquiring an additional 1,452 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares during the period. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics in the third quarter worth about $35,000. Blue Trust Inc. increased its stake in 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after buying an additional 1,025 shares during the period. Finally, Sound Income Strategies LLC bought a new stake in 10x Genomics during the 3rd quarter valued at about $46,000. Institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.